Compare AbbVie Inc (ABBV) vs Axon Enterprise Inc (AXON) Price & Performance

ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.

Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.

Axon Enterprise (AXON) trades at $571.01, up 9.29% with strong momentum following Q2 2026 results showing 35% revenue growth and 10 consecutive quarters above 30% expansion. Technical indicators show bullish moving averages with current price near resistance at $587. The company maintains dominant positioning in public safety technology with accelerating AI and counter-drone business segments driving future growth potential.

Axon presents compelling growth prospects with raised 2026 revenue guidance of 32-34% and expanding software ecosystem, though elevated valuations (P/E 248) and margin pressures from service mix shifts warrant caution. Analyst consensus remains strongly bullish with $685 price target representing 20% upside potential from current levels.